You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Minimally Invasive Cardiac Monitor for Neonatal and Pediatric ICU

    SBC: TRANSONIC SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Currently there exists no technology for routine measurement of cardiac output (CO) in neonates (0.4-2.5Kg) and low weight pediatric (2.5Kg+) patients in the intensive care unit (ICU). Accurate measurement of CO would a llow for better assessment of therapies and thereby improve patient health care. Conventional methods used with adults for routine CO measureme ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  2. ElectronicTextile Antennas

    SBC: Applied Radar, Inc.            Topic: SB021014

    Long-duration wide-area surveillance missions increasingly are space-based. MEO orbits offer space-based radar systems more time on station, but require very large array apertures on the order of 100m in diameter. Achieving larger apertures with smaller, lighter launch packages and stable on-orbit pointing is a challenge that E-Textiles promises to meet. Textile processes can be used to achieve a ...

    SBIR Phase II 2008 Department of DefenseArmy
  3. Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis

    SBC: Innovimmune Biotherapeutics Holding, LLC            Topic: NIAID

    DESCRIPTION provided by applicant There are unmet medical needs in the limited biologic therapeutics for adults with rheumatoid arthritis RA associated with $ billion annual US health care and societal costs These are due to inadequate efficacy prohibitive costs poor adherence and safety issues infections andamp malignancies Oral small molecule based therapies are warranted due to ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. The Potential to Immunocloak Renal Allografts

    SBC: BREONICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The focus of this project is a novel immunomodifying therapy that provides protection from early allograft rejection in the absence of the standard toxic systemic immunosuppressive drug regimens This novel therapy is a nano barrier membrane called NB LVF consisting of a matrix made of laminin vitrogen fibronectin and type IV collagen NB LVF is applied to ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia

    SBC: INTRA-CELLULAR THERAPIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal is submitted as a Phase II SBIR application, pursuant to our existing Phase I grant, which was funded in response to the NIMH Program Announcement #PA-02-027 entitled: "Pharmacological agents and drugs for mental disorders". The development of new pharmaceuticals for neuropsychiatric disorders is limited by the lack of rapid and effective methods ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Synthetic microparticle malaria vaccine

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant This Phase II project will develop a novel synthetic microparticle vaccine for malaria using the T BT epitopes of the circumsporozoite CS protein of Plasmodium falciparum the causative agent of human malaria There is no approved vaccine for malaria a disease that causes up to million new infections and million deaths each year in the developing wor ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A serologic assay to measure successful Lyme borreliosis antibiotic therapy

    SBC: L2 DIAGNOSTICS LLC            Topic: R

    DESCRIPTION provided by applicant Lyme disease LD caused by the Ixodes tick borne spirochete Borrelia burgdorferi Bb is the most common vector borne disease in the United States Despite public health preventive measures the annual confirmed case incidence has risen to over the vast majority of which occur in the Northeast Disseminated infection causes disease in the skin heart ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Direct-conversion Architecture for Naval Multi-band Satellite Communication Systems

    SBC: HYPRES INC            Topic: A04133

    HYPRES has developed a unique system architecture for an improved military satellite communications (MILSATCOM) receiver. This is based on direct conversion of the RF waveform to digital format using an ultrafast analog-to-digital conversion (ADC), followed by ultrafast digital processing. The proposed receiver uses both superconductor and semiconductor circuits, both digital and analog, within t ...

    SBIR Phase II 2008 Department of DefenseNavy
  9. Novel Miniature Inertial Igniters for Thermal Batteries

    SBC: OMNITEK PARTNERS LLC            Topic: A06049

    The primary objective of this project is to develop a number of classes of novel miniature inertial igniters for thermal batteries that are suitable for gun-fired munitions and mortars. As part of the Phase I efforts, systematic methods have been developed for determining the performance of miniature inertial igniter concepts to all no-fire acceleration profiles, including those due to accidental ...

    SBIR Phase II 2008 Department of DefenseArmy
  10. Refanalin for lung preservation and transplantation

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Lung transplantation is the only effective treatment modality for patients with end-stage lung disease. Ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of the lung is a major immu ne-independent factor adversely affecting early graft function, graft viability and recipient morbidity and mortality. Marginal donor lungs, ar ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government